In order to avoid repeating the same errors as a few months ago, the European Commission is organizing itself to best prepare the fight against the new variants of Covid-19.

And for the sake of anticipation, Brussels is even already looking into the schedule for deliveries of future vaccines adapted to mutations in the virus.

We have to believe that the European Commission has learned from the failures of the European vaccination strategy.

Its president, Ursula Vonderleyen, presents this Wednesday a strategy for act 2 of the health crisis.

The objective for Brussels, this time to better prepare the fight against the new variants of Covid-19 and to get in battle order to anticipate more quickly and more effectively a possible rebound of the epidemic.

>> Find the morning show of the day in replay and podcast here

Shorten procedures for new vaccines 

The Commission has therefore already planned to conclude new contracts with manufacturers or to update existing contracts for future vaccines adapted to mutations in the virus.

Scared by the delays of recent weeks, Brussels insists on the need for a detailed plan and a credible timetable for future deliveries.  

The approval procedures of the European Medicines Agency will also be shortened for this new generation of vaccine and less data will have to be provided.

A European network for clinical trials will also facilitate the recruitment of volunteers and the sharing of information between different countries. 

A life-size test

At the same time, work will be carried out with manufacturers to secure supply chains, assess their needs and identify bottlenecks that could slow everything down. 

CORONAVIRUS ESSENTIALS

> The English variant would cause slightly different symptoms

> Not recommended for people over 65, who will be injected with the AstraZeneca vaccine? 

> Audio, webcams ... When technology adapts to teleworking

> Containment is good for the planet

> How will the vaccination passport work in Denmark?

A completely new mission for Europe, which acts as a pilot program.

Because this life-size test serves above all to chart the course of what will be done in the coming years by the HERA agency, the future European agency for bio-defense.